BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk

Dow Jones

Jun 22

0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. "The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships." BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

June 22, 2026 03:56 ET (07:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2645404262"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645404262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645404262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 15:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645404262","market":"sg","top_or_hot":-1,"title":"BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 03:56 ET (07:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 15:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 03:56 ET (07:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRCTF","symbol_name":"BIOARCTIC AB","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645404262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645404262","pubTimestamp":1782114960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRCTF":"BIOARCTIC AB","BK4139":"生物科技"},"translate_title":"BioArctic的第四笔BrainTransporter交易标志着平台价值不断增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRCTF":1.91},"content_text":"0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 03:56 ET (07:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}